173 related articles for article (PubMed ID: 24991188)
81. Label-free proteomics reveals decreased expression of CD18 and AKNA in peripheral CD4+ T cells from patients with Vogt-Koyanagi-Harada syndrome.
Mao L; Yang P; Hou S; Li F; Kijlstra A
PLoS One; 2011 Jan; 6(1):e14616. PubMed ID: 21297967
[TBL] [Abstract][Full Text] [Related]
82. Vogt-Koyanagi-Harada syndrome associated with cutaneous malignant melanoma: an 11-year follow-up.
Aisenbrey S; Lüke C; Ayertey HD; Grisanti S; Perniok A; Brunner R
Graefes Arch Clin Exp Ophthalmol; 2003 Dec; 241(12):996-9. PubMed ID: 14618342
[TBL] [Abstract][Full Text] [Related]
83. In silico prediction of binding of putative antigenic peptides to HLA-DRB1 alleles in Vogt-Koyanagi-Harada disease.
Prasad PS; Levinson RD
Clin Immunol; 2005 Aug; 116(2):143-8. PubMed ID: 15927531
[TBL] [Abstract][Full Text] [Related]
84. Induction of CD4+ Th1 lymphocytes that recognize known and novel class II MHC restricted epitopes from the melanoma antigen gp100 by stimulation with recombinant protein.
Parkhurst MR; Riley JP; Robbins PF; Rosenberg SA
J Immunother; 2004; 27(2):79-91. PubMed ID: 14770079
[TBL] [Abstract][Full Text] [Related]
85. HLA-DRB1*04:05 is involved in the development of Vogt-Koyanagi-Harada disease-like immune-related adverse events in patients receiving immune checkpoint inhibitors.
Takeuchi M; Meguro A; Nakamura J; Chikagawa R; Osada R; Shibuya E; Hasumi Y; Yamada N; Ishihara M; Mizuki N
Sci Rep; 2023 Aug; 13(1):13580. PubMed ID: 37604934
[TBL] [Abstract][Full Text] [Related]
86. Application of revised diagnostic criteria for vogt-koyanagi-harada disease in Japanese patients.
Yamaki K; Hara K; Sakuragi S
Jpn J Ophthalmol; 2005; 49(2):143-8. PubMed ID: 15838732
[TBL] [Abstract][Full Text] [Related]
87. Vogt-Koyanagi-Harada disease.
Damico FM; Kiss S; Young LH
Semin Ophthalmol; 2005; 20(3):183-90. PubMed ID: 16282153
[TBL] [Abstract][Full Text] [Related]
88. Chemokine profile in the cerebrospinal fluid and serum of Vogt-Koyanagi-Harada disease.
Miyazawa I; Abe T; Narikawa K; Feng J; Misu T; Nakashima I; Fujimori J; Tamai M; Fujihara K; Itoyama Y
J Neuroimmunol; 2005 Jan; 158(1-2):240-4. PubMed ID: 15589059
[TBL] [Abstract][Full Text] [Related]
89. Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma.
Yeh S; Karne NK; Kerkar SP; Heller CK; Palmer DC; Johnson LA; Li Z; Bishop RJ; Wong WT; Sherry RM; Yang JC; Dudley ME; Restifo NP; Rosenberg SA; Nussenblatt RB
Ophthalmology; 2009 May; 116(5):981-989.e1. PubMed ID: 19410956
[TBL] [Abstract][Full Text] [Related]
90. PDCD1 genes may protect against extraocular manifestations in Chinese Han patients with Vogt-Koyanagi-Harada syndrome.
Meng Q; Liu X; Yang P; Hou S; Du L; Zhou H; Kijlstra A
Mol Vis; 2009; 15():386-92. PubMed ID: 19234630
[TBL] [Abstract][Full Text] [Related]
91. Vogt-Koyanagi-Harada disease developed during chemotherapy for Hodgkin lymphoma: a case report.
Koyama M; Nishijima E; Honda T; Gonmori-Ohta C; Sasamoto T; Tanaka K; Watanabe A; Nakano T; Akiyama M
BMC Ophthalmol; 2024 Mar; 24(1):115. PubMed ID: 38481205
[TBL] [Abstract][Full Text] [Related]
92. Disturbed expression of Fas/FasL on CD4(+) and CD8(+)T cells in Behcet's disease, Vogt-Koyanagi-Harada syndrome, and idiopathic anterior uveitis.
Yang P; Ji L; Zhou H; Huang X; Xie C; Jin H; Chen L; Kijlstra A
Ocul Immunol Inflamm; 2001 Sep; 9(3):185-91. PubMed ID: 11815887
[TBL] [Abstract][Full Text] [Related]
93. HLA-DRB1*0405 is the predominant allele in Brazilian patients with Vogt-Koyanagi-Harada disease.
Goldberg AC; Yamamoto JH; Chiarella JM; Marin ML; Sibinelli M; Neufeld R; Hirata CE; Olivalves E; Kalil J
Hum Immunol; 1998 Mar; 59(3):183-8. PubMed ID: 9548078
[TBL] [Abstract][Full Text] [Related]
94. Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramers.
Bioley G; Jandus C; Tuyaerts S; Rimoldi D; Kwok WW; Speiser DE; Tiercy JM; Thielemans K; Cerottini JC; Romero P
J Immunol; 2006 Nov; 177(10):6769-79. PubMed ID: 17082590
[TBL] [Abstract][Full Text] [Related]
95. Correlation between visual acuity and human leukocyte antigen DRB1*04 in patients with Vogt-Koyanagi-Harada disease.
Misawa N; Tagami M; Kohno T; Honda S
BMC Ophthalmol; 2019 Nov; 19(1):214. PubMed ID: 31699055
[TBL] [Abstract][Full Text] [Related]
96. Vogt-Koyanagi-Harada disease: review of a rare autoimmune disease targeting antigens of melanocytes.
Lavezzo MM; Sakata VM; Morita C; Rodriguez EE; Abdallah SF; da Silva FT; Hirata CE; Yamamoto JH
Orphanet J Rare Dis; 2016 Mar; 11():29. PubMed ID: 27008848
[TBL] [Abstract][Full Text] [Related]
97. Diagnosis and classification of Vogt-Koyanagi-Harada disease.
Sakata VM; da Silva FT; Hirata CE; de Carvalho JF; Yamamoto JH
Autoimmun Rev; 2014; 13(4-5):550-5. PubMed ID: 24440284
[TBL] [Abstract][Full Text] [Related]
98. Vogt-Koyanagi-Harada disease and HLA type in Italian patients.
Pivetti-Pezzi P; Accorinti M; Colabelli-Gisoldi RA; Pirraglia MP
Am J Ophthalmol; 1996 Dec; 122(6):889-91. PubMed ID: 8956647
[TBL] [Abstract][Full Text] [Related]
99. Inhibitory effect of Cyclosporin A and corticosteroids on the production of IFN-gamma and IL-17 by T cells in Vogt-Koyanagi-Harada syndrome.
Liu X; Yang P; Lin X; Ren X; Zhou H; Huang X; Chi W; Kijlstra A; Chen L
Clin Immunol; 2009 May; 131(2):333-42. PubMed ID: 19200788
[TBL] [Abstract][Full Text] [Related]
100. Upregulation of T-bet expression in peripheral blood mononuclear cells during Vogt-Koyanagi-Harada disease.
Li B; Yang P; Zhou H; Huang X; Jin H; Chu L; Gao Y; Zhu L; Kijlstra A
Br J Ophthalmol; 2005 Nov; 89(11):1410-2. PubMed ID: 16234441
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
